CANADA RESEARCH ROUNDUP-CCL Industries, Stantec, Terravest Industries
Aug 15 (Reuters) - Securities analysts revised their ratings and price targets on several Canadian companies including CCL Industries, Stantec and Terravest Industries on Friday.
HIGHLIGHTS
* Bank of Montreal BMO.TO: BofA Global Research cuts price objective to C$159 from C$160 |
* CCL Industries Inc CCLb.TO: BMO raises target price to C$95 from C$91 |
* Stantec Inc STN.TO: Raymond James raises target price to C$160 from C$155 |
* Terravest Industries Inc TVK.TO: BMO cuts target price to C$175 from C$180 |
* Wesdome Gold Mines Ltd WDO.TO: Stifel cuts to hold from buy |
Following is a summary of research actions on Canadian companies reported by Reuters on Friday. Stock entries are in alphabetical order.
* Autocanada Inc ACQ.TO: CIBC raises target price to C$32.50 from C$27.50 |
* Bank of Montreal BMO.TO: BofA Global Research cuts price objective to C$159 from C$160 |
* Bird Construction Inc BDT.TO: Stifel cuts target price to C$34 from C$37 |
* CCL Industries Inc CCLb.TO: BMO raises target price to C$95 from C$91 |
* KBro Linen Inc KBL.TO: TD Cowen raises target price to C$55 from C$50 |
* Mattr Corp MATR.TO: Stifel cuts target price to C$12 from C$15 |
* National Bank of Canada NA.TO: BofA Global Research raises PT to C$166 from C$154 |
* North American Construction Group Ltd NOA.TO: Canaccord Genuity cuts PT to C$19 from C$24.50 |
* North American Construction Group Ltd NOA.TO: CIBC cuts PT to C$22 from C$36 |
* North American Construction Group Ltd NOA.TO: CIBC cuts to neutral from outperformer |
* Pollard Banknote Ltd PBL.TO: Raymond James cuts target price to C$34 from C$39 |
* Stantec Inc STN.TO: Raymond James raises target price to C$160 from C$155 |
* Stantec Inc STN.TO: RBC raises target price to C$153 from C$150 |
* Stantec Inc STN.TO: Stifel cuts target price to C$160 from C$165 |
* Sylogist Ltd SYZ.TO: Stifel cuts target price to C$9 from C$12 |
* TD Bank Group TD.TO: BofA Global Research ups PT to C$113 from C$109 |
* Terravest Industries Inc TVK.TO: BMO cuts target price to C$175 from C$180 |
* Terravest Industries Inc TVK.TO: National Bank of Canada cuts target price to C$185.00 from C$200.00 |
* Wesdome Gold Mines Ltd WDO.TO: Stifel cuts target price to C$20.5 from C$24 |
* Wesdome Gold Mines Ltd WDO.TO: Stifel cuts to hold from buy |
Related Articles
Costco FY2025 Q4 Earnings Preview: Decoding Growth Drivers and Market Bets Amid Sky-High Valuation
TradingKey - Since the release of Costco's fiscal 2025 third-quarter earnings report, its stock performance has slightly underperformed the S&P 500 index. After a significant year-to-date rally, the stock has entered a consolidation phase, exhibiting a contracting triangle pattern, reflecting...
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilize
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks ahead
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.
